Indoco's AnaCipher CRO receives ANVISA Brazil approval for clinical and bioanalytical facilities
Indoco Remedies' CRO AnaCipher has received ANVISA Brazil approval for its clinical and bioanalytical facilities; the inspection was conducted from March 30, 2026 to April 7, 2026.
By ScoutQuest · · 1 min read
- Regulatory approval
- ANVISA Brazil approval for its clinical and bioanalytical facilities
- Inspection period
- March 30, 2026 to April 7, 2026
- Authorized studies
- bioavailability and bioequivalence studies for submission to Brazil
- Release
- Press release
🔬 AnaCipher, the clinical research organisation of Indoco Remedies, is now authorised to conduct bioavailability and bioequivalence studies for submission to Brazil, along with associated bioanalytical support, in accordance with ANVISA regulatory requirements.
🏭 Managing Director Aditi Panandikar said the approval reflects the CRO's quality management systems and enhanced its ability to support pharmaceutical companies conducting studies for Brazil and expanding across Latin America, according to the release.
🔬 The company says the approval strengthens AnaCipher's international regulatory footprint and reinforces its position as a partner for global clinical research programmes.
Also from Indoco Remedies
Indoco Remedies files audio recording of Q2/H1 FY27 earnings conference call held 27 October 2026
27 Oct 2026
Indoco Remedies shares reacted to Q2 results
27 Oct 2026
Q2 results approved; auditor's emphasis of matter flags going-concern doubt at two subsidiaries
27 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.